We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $90.64 · 11 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Assessing Merit Medical Systems (MMSI) After Share Price Slide And Conflicting Valuation Signals - simplywall.st
Assessing Merit Medical Systems (MMSI) After Share Price Slide And Conflicting Valuation Signals simplywall.st
A Quick Look at Today's Ratings for Merit Medical Systems(MMSI.US), With a Forecast Between $74 to $100 - Moomoo
A Quick Look at Today's Ratings for Merit Medical Systems(MMSI.US), With a Forecast Between $74 to $100 Moomoo
Merit Medical Systems stock (US59001A1025): valuation metrics in focus after recent trading around t - AD HOC NEWS
Merit Medical Systems stock (US59001A1025): valuation metrics in focus after recent trading around t AD HOC NEWS
Merit Medical Systems Inc (MMSI) Shares Fall 3.1% -- What GF Sco - GuruFocus
Merit Medical Systems Inc (MMSI) Shares Fall 3.1% -- What GF Sco GuruFocus
Why Merit Medical (MMSI) is a Top Growth Stock for the Long-Term - Yahoo Finance
Why Merit Medical (MMSI) is a Top Growth Stock for the Long-Term Yahoo Finance
2 Reasons to Avoid MMSI and 1 Stock to Buy Instead
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | After market close (AMC) | $0.96 | — | — | $405.28M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $0.49 | — | — | $355.35M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $1.57 | — | — | $1B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $1.09 | — | — | $661.51M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 02. | Canaccord Genuity | — | Maintain | Buy → Buy | — | Canaccord Genuity: Buy |
| 2026. 05. 02. | JP Morgan | — | Maintain | Overweight → Overweight | — | JP Morgan: Overweight |
| 2026. 05. 01. | Wells Fargo | — | Maintain | Equal-Weight → Equal-Weight | — | Wells Fargo: Equal-Weight |
| 2026. 05. 01. | Needham | — | Maintain | Buy → Buy | — | Needham: Buy |
| 2026. 04. 20. | Barrington Research | — | Maintain | Outperform → Outperform | — | Barrington Research: Outperform |
| 2026. 04. 18. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.